How Much Can Ejection Fraction Improve?

Ejection fraction can improve by anywhere from a few percentage points to a near-complete return to normal, depending on what caused it to drop in the first place and how effectively that cause is treated. Someone with heart failure from a blocked coronary artery who gets timely revascularization might see their EF climb from the mid-30s into the low 50s. A person whose weakened heart was driven entirely by a fast, abnormal rhythm can recover almost completely once the arrhythmia is controlled. The range is wide enough that cardiologists now recognize “heart failure with improved ejection fraction” as its own category, distinct from the kind that never gets better.

What Counts as “Improved” Ejection Fraction

A normal resting ejection fraction falls roughly between 50% and 70%. Heart failure with reduced ejection fraction, the most studied form of heart failure, is defined by an EF at or below 40%. The term “heart failure with improved ejection fraction,” or HFimpEF, describes patients who once had that reduced EF but have since climbed back above 40%.¹ There is no single agreed-upon threshold for how many points of improvement qualify. Some researchers require an absolute increase of at least 10 percentage points, while the broadest definitions simply require crossing the 40% line from below. Guidelines have not settled on a specific cutoff, which means the reported rates of “recovery” vary considerably across studies depending on how strictly they define it.²

This distinction matters because an EF that improves from 25% to 38% is clinically meaningful even though the patient technically still has a reduced EF. Conversely, an improvement from 39% to 42% crosses the definitional boundary but represents a much smaller physiological change. The numbers tell a story, but only in context.

How Standard Heart Failure Medications Drive Improvement

The foundation of EF recovery in most patients is guideline-directed medical therapy. The standard drug classes include blockers of the renin-angiotensin system (ACE inhibitors, ARBs, or the newer combination drug sacubitril/valsartan), beta-blockers, and mineralocorticoid receptor antagonists. SGLT2 inhibitors, originally developed for diabetes, are now part of the standard regimen across the ejection fraction spectrum because of their cardiovascular benefits.³

One study of patients with reduced EF who were started on sacubitril/valsartan found measurable structural improvements: the heart chambers shrank and the left ventricular mass dropped, both signs that the heart was remodeling in a healthier direction.⁴ The degree of improvement from medications alone varies, but in real-world registries, a substantial minority of patients on full medical therapy cross the 40% threshold and enter the “improved” category. The gains tend to unfold over months rather than days, and continuing all medications at target doses matters. In a large registry of nearly 8,700 patients whose EF improved, stopping certain drug classes was tied to worse outcomes: withdrawing ACE inhibitors, ARBs, or sacubitril/valsartan raised the risk of cardiovascular death or hospitalization by about 38%, and stopping mineralocorticoid antagonists raised it by about 36%.⁵

Device Therapy and Super-Responders

Cardiac resynchronization therapy, or CRT, uses a specialized pacemaker to coordinate the timing of the heart’s contractions. In patients whose heart failure is accompanied by an electrical delay in the heartbeat, CRT can produce significant structural improvement, with the heart chambers shrinking and the EF rising. All pacing modes tested in one randomized trial showed meaningful gains in EF and stroke volume.⁶

A subset of CRT patients, sometimes called “super-responders,” experience especially dramatic recoveries. In the MADIT-CRT trial, super-responders gained an average of about 17.5 percentage points in EF.⁷ That kind of jump can take someone from severe heart failure territory into the normal range. Super-responders also have far fewer dangerous heart rhythm events over the following years, suggesting that the improvement is not just a number on an echocardiogram but a genuine change in arrhythmia risk. In one study, the five-year rate of needing a defibrillator shock was about 2.7% in super-responders versus roughly 14% in those who responded less robustly.⁸

Revascularization for Ischemic Heart Disease

When heart failure is caused by coronary artery disease, restoring blood flow to the heart muscle through bypass surgery or stenting can unlock substantial EF recovery, but only if enough of the affected muscle is still alive. Among patients with a starting EF below 40% who underwent coronary intervention, the median improvement was about 6 percentage points, though individual results spread widely.⁹ In patients whose muscle was viable and responded well, mean EF climbed from roughly 36% before the procedure to about 52% afterward.¹⁰

Bypass surgery tends to produce slightly larger gains than stenting in patients with multiple blocked arteries and poor heart function, likely because bypass can deliver more complete revascularization.¹¹ The critical variable is how much of the weak muscle is “hibernating” (alive but underperfused) versus scarred (dead and replaced with fibrous tissue). This is why imaging to assess viability before a revascularization procedure is so important: if the muscle is mostly scar, no amount of new blood flow will bring it back.

Reversible Causes That Allow the Largest Recoveries

Some forms of heart failure are driven by a specific insult that, once removed, allows the heart to bounce back almost entirely. These are the cases where the EF improvement can be most dramatic.

Tachycardia-induced cardiomyopathy occurs when a persistent fast heart rhythm exhausts the heart muscle. In a study of 81 children with this condition, baseline EF was a median of 28%, and the median time to recovery of systolic function was about 51 days once the arrhythmia was controlled.¹² Adults with the same condition follow a similar pattern: control the rate, and the heart often recovers. The same principle applies to frequent premature ventricular contractions (PVCs). When PVCs are very frequent and are successfully ablated, EF can recover, though the origin of the PVC on the right side of the heart was a negative predictor in one cardiac MRI study.¹³

Takotsubo cardiomyopathy, sometimes called “broken heart syndrome,” is triggered by sudden emotional or physical stress and can cause a dramatic temporary drop in EF. Recovery is usually fast: in one analysis, the median time to EF recovery was 25 days, with half of patients recovering within about a week.¹⁴ Alcohol-related and drug-related cardiomyopathies can also reverse substantially if the offending substance is eliminated, though the degree of recovery depends on how long the exposure lasted and how much irreversible damage accumulated.

What Exercise and Cardiac Rehabilitation Add

Exercise alone is not going to take an EF from 25% to 55%, but it provides a consistent, clinically meaningful boost on top of other treatments. A meta-analysis covering dozens of trials found that moderate-intensity continuous exercise improved EF by about 4 percentage points on average in people with reduced EF. In trials lasting six months or longer, the improvement was closer to 6 points.¹⁵ High-intensity interval training produced similar gains. Resistance training by itself did not significantly change EF, though it has other benefits for functional capacity.

In a randomized trial of cardiac rehabilitation in coronary artery disease patients, the exercise group saw EF climb from about 47% to roughly 62%, while the control group stayed flat.¹⁶ That is a larger jump than the meta-analysis average, likely because the trial population had milder dysfunction to begin with and room to improve. The point is that structured exercise is one of the few interventions that reliably nudges EF upward across multiple types of heart disease, and it costs nothing beyond effort and time.

What Predicts Whether Your EF Will Improve

Not everyone’s EF responds equally to treatment, and researchers have spent considerable effort identifying who is most likely to recover. A few consistent patterns emerge.

Starting EF matters. As counterintuitive as it sounds, patients with very low starting EFs sometimes show the largest absolute gains, though they may not reach normal. In one real-world cohort of patients wearing a defibrillator vest, the strongest predictor of EF recovery was the initial EF itself: for every one-point increase in baseline EF, the odds of recovery nearly doubled.¹⁷ This makes sense: someone starting at 30% has more room to recover than someone starting at 15%, even though both are severely impaired.

The amount of scar in the heart is one of the strongest negative predictors. Scar tissue does not contract and does not recover. In patients with ischemic cardiomyopathy, the total scar burden on cardiac imaging predicted follow-up EF, and viable muscle in the territory of the left anterior descending artery was an independent predictor of improvement.¹⁸ An MRI study of patients undergoing bypass surgery found that having four or fewer scarred heart segments predicted recovery with high accuracy, while greater scar burden was the strongest barrier to improvement.¹⁹

The cause of heart failure also shapes the ceiling. Non-ischemic causes, where the muscle has not been killed by a heart attack but is merely stunned, stressed, or inflamed, tend to have higher recovery potential than ischemic causes with established scar. Younger age, shorter duration of heart failure, female sex, and absence of diabetes are also generally associated with better odds, though none of these guarantees improvement.

How Long Recovery Takes

The timeline varies enormously by cause. Takotsubo cardiomyopathy can resolve in a week. Tachycardia-induced cardiomyopathy usually takes one to two months. Drug-induced recovery on standard heart failure medications typically requires three to six months of optimized therapy before EF is rechecked, and some patients continue to improve beyond that. The meta-analysis on exercise found that longer training programs produced bigger EF gains, which suggests the heart’s remodeling response continues well past the first few months.

For patients who have had CRT devices implanted, meaningful improvement often appears within the first three to six months, with some continued remodeling over the following year. Revascularization improvements can be detectable within weeks if the muscle was hibernating, though the full benefit may take several months to declare itself.

Why a Recovered EF Does Not Mean You Are Cured

This is the most commonly misunderstood aspect of EF improvement, and it has real consequences. When a patient sees their EF go from 30% to 55% on repeat imaging, the natural instinct is to think the problem is solved. It often is not. The TRED-HF trial tested what happens when you systematically withdraw medications from patients with recovered dilated cardiomyopathy. Within six months, 44% of patients whose medications were stopped relapsed, compared with none in the group that continued treatment.²⁰ When the continuation group later also attempted withdrawal, about 36% of them relapsed too.

The large registry data reinforce this point from a different angle. Stopping ACE inhibitors, ARBs, sacubitril/valsartan, or mineralocorticoid antagonists after EF improved was associated with a meaningfully higher risk of cardiovascular death or hospitalization.⁵ Beta-blockers were an interesting exception in the overall cohort, where withdrawal was not associated with worse outcomes, though in the subgroup whose improved EF was still between 40% and 49% rather than fully normalized, stopping beta-blockers did appear harmful. The takeaway for most patients is that heart failure medications are managing the underlying condition, not curing it. Removing them often allows the disease process to reassert itself.

The Value of Improvement Even When It Is Incomplete

Patients who improve their EF have substantially better long-term outcomes than those who do not, even if they do not reach a normal EF. In a study of patients who developed heart failure after a heart attack, those who achieved HFimpEF had roughly 62% lower risk of death from any cause compared with patients whose EF stayed reduced.²¹ This survival advantage held up over both the early and later follow-up periods. So while full normalization is the aspirational target, any upward movement matters.

What Is Happening Inside the Heart

When the heart improves, it is not just pumping harder. The improvement reflects actual structural and cellular remodeling in reverse. Heart muscle cells shrink back toward their normal size, the internal scaffolding of the cells reorganizes, and the energy-producing machinery inside the cells starts working more efficiently again. Mitochondria, the power plants of the cell, recover their ability to produce energy and generate fewer of the toxic byproducts that damage the heart when it is failing.²² The calcium-handling systems that control each heartbeat normalize, restoring the precise coordination between electrical signals and mechanical contraction.

Studies of patients supported by mechanical heart pumps (LVADs), where researchers can take small tissue samples at the time the device goes in and again later, have shown that this recovery involves complex changes in gene activity. Some disease-related genes quiet down while others ramp up, and the pattern does not simply revert to a normal heart. Recovery looks like its own distinct biological state, with some features of the failing heart persisting even after function has improved.²³ This insight helps explain why stopping medications after EF improvement can lead to relapse: the underlying biology has not fully returned to its pre-disease state, even when the pump function looks better.

Mechanical Heart Pumps and Recovery

Left ventricular assist devices were originally designed as a bridge to heart transplant, but clinicians noticed that some patients improved so much on the device that they no longer needed a new heart. In a prospective study of LVAD patients, average EF rose from about 17% to roughly 34% after 30 days of mechanical support, and about a third of patients reached an EF above 40% when the device workload was partially reduced.²⁴ Heart chamber size dropped substantially at the same time. Not everyone who improves on an LVAD can have it removed, and the field is still working out how to identify which patients have truly recovered versus those who simply perform better while the pump is running. But these cases represent some of the most striking recoveries documented, from EFs in the teens to near-normal function.

Measurement Can Mislead

A practical issue that patients rarely hear about: EF measurement is not perfectly precise, and the technique used to measure it can shift the number by a meaningful amount. Standard echocardiography (the ultrasound most commonly used) tends to overestimate EF compared with cardiac MRI, the gold-standard method. In one study comparing the two, echocardiography overestimated EF by an average of about 7 percentage points, and in roughly 28% of patients, the two methods gave opposing answers about whether the patient qualified for a defibrillator.²⁵

This means that some apparent “improvement” in EF could partly reflect a switch in imaging technique, a different sonographer, or even just a better acoustic window on a given day. If you are tracking your own EF over time, the most reliable comparisons come from the same imaging modality, ideally at the same center. A 5-point jump measured by the same machine and the same technician is more meaningful than a 10-point jump measured by ultrasound one time and MRI the next.

Children and Heart Failure Recovery

Pediatric cardiomyopathy follows somewhat different rules. In children with heart failure and reduced EF, viral infection as the underlying trigger and treatment with intravenous immunoglobulin were both associated with better odds of EF improvement. After an average follow-up of about three years, 26 children in one study returned to a normal EF.²⁶ Children whose cardiomyopathy is driven by arrhythmia tend to recover well, as noted in the tachycardia-induced cardiomyopathy data. But not all pediatric heart failure is reversible: some children still progress to transplant or worse. The younger the child and the more identifiable and treatable the trigger, the better the chances of meaningful EF recovery.